Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jul 1;6(4):pkac044.
doi: 10.1093/jncics/pkac044.

Intensification of Androgen Deprivation Therapy in High-Risk, Nonmetastatic Prostate Cancer: Lessons From STAMPEDE

Jun Gong  1 , Edwin M Posadas  2
Affiliations
Comment

Intensification of Androgen Deprivation Therapy in High-Risk, Nonmetastatic Prostate Cancer: Lessons From STAMPEDE

Jun Gong et al. JNCI Cancer Spectr. .
No abstract available

PubMed Disclaimer

Comment on

  • Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
    James ND, Ingleby FC, Clarke NW, Amos CL, Attard G, Brawley CD, Chowdhury S, Cross W, Dearnaley DP, Gilbert DC, Gillessen S, Jones RJ, Langley RE, Macnair A, Malik ZI, Mason MD, Matheson DJ, Millman R, Parker CC, Rush HL, Russell JM, Au C, Ritchie AWS, Mestre RP, Ahmed I, Birtle AJ, Brock SJ, Das P, Ford VA, Gray EK, Hughes RJ, Manetta CB, McLaren DB, Nikapota AD, O'Sullivan JM, Perna C, Peedell C, Protheroe AS, Sundar S, Tanguay JS, Tolan SP, Wagstaff J, Wallace JB, Wylie JP, Zarkar A, Parmar MKB, Sydes MR. James ND, et al. JNCI Cancer Spectr. 2022 Jul 1;6(4):pkac043. doi: 10.1093/jncics/pkac043. JNCI Cancer Spectr. 2022. PMID: 35877084 Free PMC article. Clinical Trial.

References

    1. James ND, Ingleby F, Clarke NW, et al.Adding docetaxel to long-term hormone therapy for high- risk, non- metastatic prostate cancer: long-term survival in the STAMPEDE randomised controlled trial. JNCI Cancer Spectr. 2022. doi:10.1093/jncics/pkac043. - DOI - PubMed
    1. James ND, Sydes MR, Clarke NW, et al.; for the STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163-1177. - PMC - PubMed
    1. Clarke NW, Ali A, Ingleby FC, et al.Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019;30(12):1992-2003. - PMC - PubMed
    1. Attard G, Murphy L, Clarke NW, et al.Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447-460. - PMC - PubMed
    1. Sandler HM, Karrison T, Sartor AO, et al.Adjuvant docetaxel for high-risk localized prostate cancer: update of NRG Oncology/RTOG 0521. J Clin Oncol. 2020;38(suppl 6):333-333.

MeSH terms

LinkOut - more resources